-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29

Benzinga·10/20/2026 17:43:46
語音播報
B. Riley Securities analyst Kalpit Patel maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $29.